Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

NCT07399171 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimers Disease

Interventions

DRUG: HT-4253
OTHER: Placebo

Sponsor

Halia Therapeutics, Inc.